Administration of Interleukin-15 Peptide Improves Cardiac Function in a Mouse Model of Myocardial Infarction.
Animals
Cardiovascular Agents
/ pharmacology
Cell Death
/ drug effects
Cells, Cultured
Disease Models, Animal
Human Umbilical Vein Endothelial Cells
/ drug effects
Humans
Interleukin-15
/ pharmacology
Male
Mice, Inbred C57BL
Myocardial Infarction
/ drug therapy
Myocytes, Cardiac
/ drug effects
Neovascularization, Physiologic
/ drug effects
Recovery of Function
Stroke Volume
/ drug effects
Ventricular Function, Left
/ drug effects
Journal
Journal of cardiovascular pharmacology
ISSN: 1533-4023
Titre abrégé: J Cardiovasc Pharmacol
Pays: United States
ID NLM: 7902492
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
pubmed:
10
12
2019
medline:
15
9
2020
entrez:
10
12
2019
Statut:
ppublish
Résumé
Interleukin-15 is a pleotropic factor, capable of modulating metabolism, survival, proliferation, and differentiation in many different cell types. The rationale behind this study relates to previous work demonstrating that IL-15 is a major factor present in stem cell extracts, which protects cardiomyocytes subjected to hypoxic stress in vitro. The objective of this current study was to assess whether administration of IL-15 peptide will also show protective effects in vivo. The data indicate that administration of IL-15 reduces cell death, increases vascularity, decreases scar size, and significantly improves left ventricular ejection fraction in a mouse model of myocardial infarction.
Identifiants
pubmed: 31815824
doi: 10.1097/FJC.0000000000000764
pmc: PMC6964872
pii: 00005344-202001000-00013
doi:
Substances chimiques
Cardiovascular Agents
0
Interleukin-15
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
98-102Subventions
Organisme : NIGMS NIH HHS
ID : R25 GM048972
Pays : United States
Références
Nat Med. 2005 Apr;11(4):367-8
pubmed: 15812508
Mol Ther. 2009 Jul;17(7):1250-6
pubmed: 19384293
Am J Physiol Heart Circ Physiol. 2007 Sep;293(3):H1772-80
pubmed: 17573463
Am J Physiol Heart Circ Physiol. 2005 Sep;289(3):H1307-14
pubmed: 15908468
Int J Vasc Med. 2017;2017:2049217
pubmed: 28875043
Mol Biol Rep. 2014 Nov;41(11):7715-22
pubmed: 25103021
Am J Physiol Heart Circ Physiol. 2006 Aug;291(2):H886-93
pubmed: 16603697
Nat Med. 2013 Oct;19(10):1273-80
pubmed: 24037091
Biochem Biophys Res Commun. 1997 Apr 7;233(1):231-7
pubmed: 9144429
J Clin Invest. 2002 Apr;109(7):951-60
pubmed: 11927622
FASEB J. 2006 Apr;20(6):661-9
pubmed: 16581974
Front Physiol. 2016 Dec 20;7:626
pubmed: 28066259
J Cardiovasc Pharmacol. 2014 May;63(5):406-11
pubmed: 24805144
Endocrine. 2015 Feb;48(1):152-63
pubmed: 24647688
Circ Res. 2006 Jun 9;98(11):1414-21
pubmed: 16690882
Am J Physiol Heart Circ Physiol. 2008 Oct;295(4):H1726-35
pubmed: 18723770
Eur J Heart Fail. 2007 Aug;9(8):747-53
pubmed: 17481945
Exerc Sport Sci Rev. 2012 Jan;40(1):43-9
pubmed: 21918459
J Mol Cell Cardiol. 2009 Mar;46(3):370-7
pubmed: 19109969
Front Cardiovasc Med. 2015 Nov 30;2:36
pubmed: 26664907
Biochem Biophys Res Commun. 2009 Jul 31;385(3):324-9
pubmed: 19450559
Front Cardiovasc Med. 2019 Mar 18;6:25
pubmed: 30937305
Mol Biol Cell. 2011 Jun 15;22(12):1960-70
pubmed: 21508317
Sci Rep. 2017 Jul 31;7(1):6877
pubmed: 28761077
J Mol Cell Cardiol. 2014 Jan;66:157-64
pubmed: 24269490
Circ Res. 2004 Mar 19;94(5):678-85
pubmed: 14739163
Aging Cell. 2015 Aug;14(4):625-34
pubmed: 25902870